Merck KGaA 3
3 · Xilio Therapeutics, Inc. · Filed Oct 21, 2021
Insider Transaction Report
Form 3
Merck KGaA
10% Owner
Holdings
- (indirect: See footnote)
Series C Preferred Stock
→ Common Stock (264,765 underlying) - (indirect: See footnote)
Series B Preferred Stock
→ Common Stock (416,060 underlying)
Footnotes (3)
- [F1]The Series B Preferred Stock automatically converts into the number of shares of Common Stock as shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
- [F2]The shares are held directly by Merck Ventures B.V. Merck Ventures B.V. is a wholly owned indirect subsidiary of Merck KGaA, a publicly traded company. Merck KGaA may be deemed to have sole voting and dispositive power with respect to the shares held by Merck Ventures B.V.
- [F3]The Series C Preferred Stock automatically converts into the number of shares of Common Stock as shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.